Shell Asset Management CO Regenxbio Inc. Transaction History

Shell Asset Management CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$33.61 - $49.95 $146,405 - $217,582	-4,356 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$27.75 - $43.44 $2,331 - $3,648	-84 Reduced 1.89%	4,356 $160,000
Q1 2020 May 11, 2020	SELL	$21.5 - $54.2 $1,462 - $3,685	-68 Reduced 1.51%	4,440 $144,000
Q4 2019 Feb 13, 2020	SELL	$34.54 - $44.87 $4,559 - $5,922	-132 Reduced 2.84%	4,508 $185,000
Q3 2019 Nov 12, 2019	SELL	$31.84 - $50.88 $1,273 - $2,035	-40 Reduced 0.85%	4,640 $165,000
Q2 2019 Aug 12, 2019	SELL	$42.0 - $59.29 $4,494 - $6,344	-107 Reduced 2.24%	4,680 $240,000
Q4 2018 Feb 13, 2019	SELL	$39.11 - $75.15 $15,644 - $30,060	-400 Reduced 7.71%	4,787 $201,000
Q3 2018 Nov 13, 2018	BUY	$65.0 - $82.15 $337,155 - $426,112	5,187 New	5,187 $392,000

193

43.2M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $339M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.